Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of γ-interferon receptors

Arthur B. Raitano, Murray Korc

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Recombinant human tumor necrosis factor and recombinant human γ interferon (IFN-γ) exert synergistic growth inhibitory effects in WiDR human colorectal carcinoma cells. In this cell line, tumor necrosis factor increases IFN-γ binding. Interleukin 1 (IL-1) is a cytokine that mimics many of the biological actions of TNF. Therefore, in the present study, we investigated the effects of recombinant human IL-1 on cell growth and IFN-γ receptor expression in WiDR cells. IL-1 slightly inhibited the growth of WiDR cells, and exerted additive growth inhibitory effects in the presence of IFN-γ. IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-γ binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide. The increase in binding was associated with an increase in cell surface IFN-γ receptor protein expression as determined by Scatchard analysis of equilibrium binding data and by immunofluorescent staining with an antihuman IFN-γ receptor monoclonal antibody. IL-1 also produced a time-and dose-dependent increase in IFN-γ receptor mRNA levels that was maximal at 3 h and persisted for at least 24 h. Actinomycin D, but not cycloheximide, completely blocked the IL-1-mediated increase in IFN-γ receptor mRNA levels. However, IL-1 did not alter IFN-γ receptor mRNA half-life. These data indicate that IL-1 and IFN-γ exert additive growth inhibitory effects on colon cancer cell growth, and suggest that IL-1 increases IFN-γ receptor expression in these cells by enhancing IFN-γ mRNA levels.

Original languageEnglish (US)
Pages (from-to)636-640
Number of pages5
JournalCancer Research
Volume53
Issue number3
StatePublished - Feb 1 1993
Externally publishedYes

Fingerprint

Interferon Receptors
Interleukin-1
Colorectal Neoplasms
Cell Line
Interferons
Growth
Messenger RNA
Dactinomycin
Cycloheximide
Cell Surface Receptors
Colonic Neoplasms
Half-Life
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Staining and Labeling
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of γ-interferon receptors. / Raitano, Arthur B.; Korc, Murray.

In: Cancer Research, Vol. 53, No. 3, 01.02.1993, p. 636-640.

Research output: Contribution to journalArticle

@article{f88e44a9a36b4ffc9a8ef5a9ead79958,
title = "Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of γ-interferon receptors",
abstract = "Recombinant human tumor necrosis factor and recombinant human γ interferon (IFN-γ) exert synergistic growth inhibitory effects in WiDR human colorectal carcinoma cells. In this cell line, tumor necrosis factor increases IFN-γ binding. Interleukin 1 (IL-1) is a cytokine that mimics many of the biological actions of TNF. Therefore, in the present study, we investigated the effects of recombinant human IL-1 on cell growth and IFN-γ receptor expression in WiDR cells. IL-1 slightly inhibited the growth of WiDR cells, and exerted additive growth inhibitory effects in the presence of IFN-γ. IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-γ binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide. The increase in binding was associated with an increase in cell surface IFN-γ receptor protein expression as determined by Scatchard analysis of equilibrium binding data and by immunofluorescent staining with an antihuman IFN-γ receptor monoclonal antibody. IL-1 also produced a time-and dose-dependent increase in IFN-γ receptor mRNA levels that was maximal at 3 h and persisted for at least 24 h. Actinomycin D, but not cycloheximide, completely blocked the IL-1-mediated increase in IFN-γ receptor mRNA levels. However, IL-1 did not alter IFN-γ receptor mRNA half-life. These data indicate that IL-1 and IFN-γ exert additive growth inhibitory effects on colon cancer cell growth, and suggest that IL-1 increases IFN-γ receptor expression in these cells by enhancing IFN-γ mRNA levels.",
author = "Raitano, {Arthur B.} and Murray Korc",
year = "1993",
month = "2",
day = "1",
language = "English (US)",
volume = "53",
pages = "636--640",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Growth inhibition of a human colorectal carcinoma cell line by interleukin 1 is associated with enhanced expression of γ-interferon receptors

AU - Raitano, Arthur B.

AU - Korc, Murray

PY - 1993/2/1

Y1 - 1993/2/1

N2 - Recombinant human tumor necrosis factor and recombinant human γ interferon (IFN-γ) exert synergistic growth inhibitory effects in WiDR human colorectal carcinoma cells. In this cell line, tumor necrosis factor increases IFN-γ binding. Interleukin 1 (IL-1) is a cytokine that mimics many of the biological actions of TNF. Therefore, in the present study, we investigated the effects of recombinant human IL-1 on cell growth and IFN-γ receptor expression in WiDR cells. IL-1 slightly inhibited the growth of WiDR cells, and exerted additive growth inhibitory effects in the presence of IFN-γ. IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-γ binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide. The increase in binding was associated with an increase in cell surface IFN-γ receptor protein expression as determined by Scatchard analysis of equilibrium binding data and by immunofluorescent staining with an antihuman IFN-γ receptor monoclonal antibody. IL-1 also produced a time-and dose-dependent increase in IFN-γ receptor mRNA levels that was maximal at 3 h and persisted for at least 24 h. Actinomycin D, but not cycloheximide, completely blocked the IL-1-mediated increase in IFN-γ receptor mRNA levels. However, IL-1 did not alter IFN-γ receptor mRNA half-life. These data indicate that IL-1 and IFN-γ exert additive growth inhibitory effects on colon cancer cell growth, and suggest that IL-1 increases IFN-γ receptor expression in these cells by enhancing IFN-γ mRNA levels.

AB - Recombinant human tumor necrosis factor and recombinant human γ interferon (IFN-γ) exert synergistic growth inhibitory effects in WiDR human colorectal carcinoma cells. In this cell line, tumor necrosis factor increases IFN-γ binding. Interleukin 1 (IL-1) is a cytokine that mimics many of the biological actions of TNF. Therefore, in the present study, we investigated the effects of recombinant human IL-1 on cell growth and IFN-γ receptor expression in WiDR cells. IL-1 slightly inhibited the growth of WiDR cells, and exerted additive growth inhibitory effects in the presence of IFN-γ. IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-γ binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide. The increase in binding was associated with an increase in cell surface IFN-γ receptor protein expression as determined by Scatchard analysis of equilibrium binding data and by immunofluorescent staining with an antihuman IFN-γ receptor monoclonal antibody. IL-1 also produced a time-and dose-dependent increase in IFN-γ receptor mRNA levels that was maximal at 3 h and persisted for at least 24 h. Actinomycin D, but not cycloheximide, completely blocked the IL-1-mediated increase in IFN-γ receptor mRNA levels. However, IL-1 did not alter IFN-γ receptor mRNA half-life. These data indicate that IL-1 and IFN-γ exert additive growth inhibitory effects on colon cancer cell growth, and suggest that IL-1 increases IFN-γ receptor expression in these cells by enhancing IFN-γ mRNA levels.

UR - http://www.scopus.com/inward/record.url?scp=0027410401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027410401&partnerID=8YFLogxK

M3 - Article

C2 - 8425199

AN - SCOPUS:0027410401

VL - 53

SP - 636

EP - 640

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -